Abstract
Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1312-1326 |
| Number of pages | 15 |
| Journal | CHEST |
| Volume | 127 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2005 |
| Externally published | Yes |
Keywords
- Asthma
- Cytokines
- Eosinophils
- Inflammation
- Leukotriene receptor antagonists
- Leukotrienes
- Remodeling
- Rhinitis
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine